FY2019 EPS Estimates for Antares Pharma Inc Lifted by Analyst (NASDAQ:ATRS)

Antares Pharma Inc (NASDAQ:ATRS) – Research analysts at Piper Jaffray Companies upped their FY2019 earnings per share (EPS) estimates for Antares Pharma in a note issued to investors on Tuesday, November 5th. Piper Jaffray Companies analyst D. Amsellem now expects that the specialty pharmaceutical company will earn ($0.04) per share for the year, up from their prior estimate of ($0.05). Piper Jaffray Companies also issued estimates for Antares Pharma’s Q4 2019 earnings at $0.00 EPS, Q1 2020 earnings at $0.02 EPS, FY2020 earnings at $0.22 EPS, Q1 2021 earnings at $0.06 EPS, Q2 2021 earnings at $0.09 EPS, Q3 2021 earnings at $0.10 EPS, FY2021 earnings at $0.35 EPS, FY2022 earnings at $0.39 EPS and FY2023 earnings at $0.45 EPS.

Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings data on Tuesday, November 5th. The specialty pharmaceutical company reported $0.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.03. Antares Pharma had a negative net margin of 0.56% and a negative return on equity of 1.43%. The business had revenue of $34.31 million during the quarter, compared to the consensus estimate of $26.36 million.

Separately, BidaskClub raised shares of Antares Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, October 19th. One analyst has rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $4.05.

ATRS traded down $0.04 during trading hours on Friday, hitting $3.64. 3,597,824 shares of the company’s stock were exchanged, compared to its average volume of 1,010,181. Antares Pharma has a 12-month low of $2.53 and a 12-month high of $3.96. The firm has a 50 day moving average of $3.45 and a 200 day moving average of $3.17. The firm has a market cap of $602.51 million, a P/E ratio of -91.00 and a beta of 0.80. The company has a current ratio of 3.46, a quick ratio of 2.87 and a debt-to-equity ratio of 1.01.

Several large investors have recently made changes to their positions in ATRS. Cortina Asset Management LLC boosted its position in Antares Pharma by 100.3% during the second quarter. Cortina Asset Management LLC now owns 2,072,605 shares of the specialty pharmaceutical company’s stock worth $6,819,000 after purchasing an additional 1,037,675 shares during the period. BlackRock Inc. grew its stake in shares of Antares Pharma by 10.0% in the second quarter. BlackRock Inc. now owns 10,904,306 shares of the specialty pharmaceutical company’s stock worth $35,875,000 after purchasing an additional 993,787 shares during the last quarter. River & Mercantile Asset Management LLP bought a new stake in shares of Antares Pharma in the second quarter worth about $2,603,000. State of New Jersey Common Pension Fund D bought a new stake in shares of Antares Pharma in the third quarter worth about $2,549,000. Finally, Nuveen Asset Management LLC bought a new stake in Antares Pharma during the 2nd quarter valued at approximately $2,252,000. 38.74% of the stock is currently owned by institutional investors.

About Antares Pharma

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Recommended Story: Cost of Equity

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply